Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-20T02:40:56.732Z Has data issue: false hasContentIssue false
  • English
  • Français

Cardiovascular considerations of attention deficit hyperactivity disorder medications: a report of the European Network on Hyperactivity Disorders work group, European Attention Deficit Hyperactivity Disorder Guidelines Group on attention deficit hyperactivity disorder drug safety meeting – CORRIGENDUM

Published online by Cambridge University Press:  21 October 2011

Robert M. Hamilton ,
Eric Rosenthal ,
Martin Hulpke-Wette ,
John G. I. Graham  and
Joseph Sergeant
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
Corrigendum
Information
Cardiology in the Young , Volume 22 , Issue 1 , February 2012 , pp. 120
Copyright
Copyright © Cambridge University Press 2011

doi:10.1017/S1047951111000928, Published by Cambridge University Press, 19 July 2011.

The paper is listed as being on behalf of the European Network for Hyperactivity Disorders and the Association of European Paediatric Cardiology. This second attribution ‘Association of European Paediatric Cardiology’ was deleted from the text, and should have been deleted from the author list. The author apologises for this error.

References

1. Robert M., Hamilton, Eric, Rosenthal, Martin, Hulpke-Wette, John G. I., Graham, Joseph, Sergeant. Cardiovascular considerations of attention deficit hyperactivity disorder medications: a report of the European Network on Hyperactivity Disorders work group, European Attention Deficit Hyperactivity Disorder Guidelines Group on attention deficit hyperactivity disorder drug safety meeting. Cardiol Young 2011. Published by Cambridge University Press, 19 July 2011. doi:10.1017/S1047951111000928.Google Scholar